Posts tagged: upcoming
Card Logistics to Auction Smart Card Gaming Technology at Upcoming ICAP Patent Brokerage Fall 2011 Live IP Auction in San Francisco
CHICAGO, Sept. 27, 2011 /- ICAP Patent Brokerage , a division of ICAP plc, the world's largest intellectual property brokerage and patent auction firm, announces the auction of U.S. Patent 7,562,815 and related assets owned by Card Logistics at the upcoming Fall 2011 Live IP Auction November 17th in ...
Highlights of upcoming conference on aldosterone & the ENaC/Degenerin family of ion channels
Bethesda, Md. (Sept. 6, 2011) The American Physiological Society is sponsoring the 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels, being held September 18-22 at the Asilomar Conference Grounds in Pacific Grove, Calif. This scientific conference explores the connection between fluid balance ...
Upcoming Alzheimer’s Disease Guidelines Supported By New JNM Research
Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With proposed National Institute on Aging (NIA) and the ...
New research supports upcoming Alzheimer’s disease guidelines
Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With proposed National Institute on Aging (NIA) and the ...
New JNM research supports upcoming Alzheimer’s disease guidelines
Reston, Va. (August 1, 2011) Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With ...
New JNM research supports upcoming Alzheimer’s disease guidelines
(Society of Nuclear Medicine) Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With proposed National Institute on ...
GTx Announces Upcoming Presentations Of Effects Of Ostarine™ In Non-Small Cell Lung Cancer Patients At World Conference On Lung Cancer
GTx, Inc. (Nasdaq: GTXI) announced today that the effects of Ostarine™ (GTx-024) on physical function in patients with non-small cell lung cancer (NSCLC) will be the subject of an oral podium presentation at the 14th Annual World Conference on Lung Cancer, the annual meeting of the International Association for the ...
Phase 2 Data On Provectus’s PV-10 For Metastatic Melanoma To Be Presented At Two Upcoming Conferences
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences. On June 21, 2011, Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital ...
Uroplasty to present Urgent PC, Macroplastique products study data at upcoming meetings
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent PC Neuromodulation System and Macroplastique urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.
Anacor’s AN2728 and GSK ’052 new data to be presented at upcoming meetings
Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.
Neuralstem ALS Trial In Multiple Presentations At Upcoming American Academy Of Neurology Meeting
Neuralstem, Inc. (NYSE Amex: CUR) announced that the Phase I safety trial of its human spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is the subject of three presentations at the American Academy of Neurology (AAN) Annual Meeting, April 9-16th, in Honolulu, HI (click ...